Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, July 6, 2005 - Astellas Pharma Inc. today announced that Astellas US LLC, its wholly owned subsidiary headquartered in Deerfield, IL.(Chairman and CEO; Makoto Nishimura, Ph.D.) has executed...
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) decided at a board meeting held on June 24 to integrate its active pharmaceutical ingredient (API)...
Japan, June 10, 2005 - Astellas Pharma Inc. ("Astellas") today announced that a new dosage form of Harnal® (generic name: tamsulosin HCl), the orally disintegrating tablet "Harnal® D Tablet...
Deerfield, Ill., May 26, 2005- King Pharmaceuticals Research and Development, Inc. ("King") along with Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") announced today that they have...
Japan, May 17, 2005 - Astellas Pharmaceutical Co., Ltd.(Astellas) today announced that Astellas has decided a dissolution of Astellas Medical Care Co., Ltd., its wholly owned subsidiary engaged in...
Japan, May 16, 2005 - Astellas Pharma Inc. (Astellas) today announced its decision to withdraw from its Medical Supplies and Systems Business along with the corporate strategy to concentrate on...
Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Toichi Takenaka; "Astellas") and Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI"), a US subsidiary of Boehringer Ingelheim of...
Deerfield, IL, -- May 13, 2005, Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent MYCAMINETM (micafungin sodium) for Injection to...
Japan, April 11, 2005 - Astellas Pharma Inc. ("Astellas") today announced that the Company obtained an approval from the Ministry of Health, Labor and Welfare (MHLW) for the immunosuppressant...
April 1st, 2005 Astellas Pharma Inc. ("Astellas"), today announced that the Company, headquartered in Tokyo, Japan, was created through the merger of Yamanouchi Pharmaceutical Co., Ltd....
Follow us
